|
|
|
|
Expression pattern and promoter hypermethylation of PDLIM4 gene in patients with chronic myeloid leukemia |
|
LI Yun1, QIAN Jun1, CHEN Qin2, YAO Dong-ming1, WANG Cui-zhu1, CHAI Hai-yan1,YANG Jing1, LIN Jiang2, MA Ji-chun2, CHEN Xing-xing1, MA Yu-juan1 |
| (1.Department of Hematology, 2.Laboratory Center, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002, China) |
|
|
|
|
Abstract Objective: To analyze the expression transcript level and promoter hypermethylation of PDZ and LIM domain 4(PDLIM4) gene and the clinical correlations in Chinese patients with chronic myeloid leukemia(CML). Methods: Real-time quantitative PCR(RQ-PCR) and real-time quantitative methylation-specific PCR(RQMSP) assays were used to detect the expression and methylation status of PDLIM4 gene in the bone marrow samples from CML patients. Results: Down-regulated PDLIM4 expression was found in 8／36(22％) CML cases, with significant statistical difference compared with all 21 controls(Fisher′s Exact Test, P=0.021). There was a significant correlation between PDLIM4 expression and bcr／abl fusion transcript(r=0.434, P=0.043) in CML patients. Hypermethylation of PDLIM4 promoter was detected in 13／59(22％) CML patients, but not in all 24 controls(Fisher′s Exact Test, P=0.016). PDLIM4 hypermethylation was not correlated with blood parameters(P>0.05). The frequencies of PDLIM4 promoter hypermethylation increased during the disease progression, as it was 16％(7／44), 33％(2／6) and 44％(4／9) in chronic phase, accelerated phase and blast crisis, respectively. Conclusion: Hypermethylation of PDLIM4 promoter may be associated with the disease progression in CML.
|
|
Received: 13 November 2012
|
|
|
|
| ［1］ Jelinek J, Gharibyan V, Estecio MR, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia［J］. PLoS One, 2011, 6(7): e22110.［2］ Kiess M, Scharm B, Aguzzi A, et al. Expression of ril, a novel LIM domain gene, is down-regulated in Hras-transformed cells and restored in phenotypic revertants［J］. Oncogene, 1995, 10(1):61-68.［3］ Boumber YA, Kondo Y, Chen X, et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis［J］. Cancer Res, 2007, 67(5):1997-2005.［4］ Vanaja DK, Ballman KV, Morlan BW, et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer［J］. Clin Cancer Res, 2006, 12(4):1128-1136.［5］ Vanaja DK, Grossmann ME, Cheville JC, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth［J］. Cancer Inverst, 2009, 27(3):264-272.［6］ 张之南,沈悌.血液病诊断及疗效标准［M］.2版. 北京:科学出版社, 1998:219-228.［7］ Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patientsusing ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction(RQ-PCR)—a Europe against cancer program［J］. Leukemia, 2003, 17(12):2474-2486.［8］ Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight［J］. Nucleic Acids Res, 2005, 33(21):6823-6836.［9］ Calabretta B, Perrotti D. The biology of CML blast crisis ［J］. Blood, 2004, 103(11):4010-4022.［10］ Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer［J］. Nat Rev Cancer, 2007, 7(6):441-453.［11］ Qian J, Wang YL, Lin J, et al. Aberrant methylation of the death-associated protein kinase 1(DAPK1) CpG island in chronic myeloid leukemia［J］. Eur J Haematol, 2009, 82(2):119-123. |
|
|
|
2013, Vol. 23 
